Salmon-calcitonin nasal spray in Paget's disease of bone: Preliminary results in five patients

1985 ◽  
Vol 37 (6) ◽  
pp. 577-580 ◽  
Author(s):  
J. Y. Reginster ◽  
A. Albert ◽  
P. Franchimont
Keyword(s):  
Nasal Spray ◽  
Salmon Calcitonin ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Preliminary Results ◽  
Calcitonin Nasal Spray

scholarly journals Treatment of Paget's Disease of Bone with Synthetic Salmon Calcitonin

BMJ ◽  
1974 ◽  
Vol 3 (5933) ◽  
pp. 727-731 ◽  
Author(s):  
J. A. Kanis ◽  
D. B. Horn ◽  
R. D. M. Scott ◽  
J. A. Strong
Keyword(s):  
Salmon Calcitonin ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Synthetic Salmon Calcitonin

A comparison of the acute effects of subcutaneous and intranasal calcitonin

1990 ◽  
Vol 78 (2) ◽  
pp. 215-219 ◽  
Author(s):  
D. P. O'Doherty ◽  
D. R. Bickerstaff ◽  
E. V. McCloskey ◽  
R. Atkins ◽  
N. A. T. Hamdy ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Nasal Spray ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Acute Effects ◽  
Intranasal Route ◽  
Low Bone Turnover ◽  
Dose Dependent

1. We studied the acute effects of intranasal and subcutaneous calcitonin in 40 patients with active Paget's disease of bone. Patients received a single dose of either 400 units of calcitonin delivered as a nasal spray, or 1, 10 or 100 units of subcutaneous calcitonin, or placebo. 2. Subcutaneous salmon calcitonin, administered at doses of 1, 10 and 100 units to nine patients with Paget's disease of bone, induced a dose-dependent fall in the serum calcium. This calcium-lowering effect was not seen with a second group of nine patients receiving placebo. 3. The lower doses of calcitonin had significant effects, and these were more pronounced in patients with lower rates of bone turnover. 4. Four hundred units of calcitonin administered as a nasal spray induced effects qualitatively similar to those seen with subcutaneous calcitonin, with an efficacy equivalent to approximately 30 units of subcutaneous calcitonin. 5. We conclude that the bioequivalence of calcitonin given by intranasal insufflation is low compared with its parenteral administration. The intranasal route may be more appropriate for managing patients with disorders associated with low bone turnover.

The Therapeutic Uses of Calcitonin

1978 ◽  
Vol 23 (2) ◽  
pp. 161-165 ◽  
Author(s):  
T. J. Martin
Keyword(s):  
Bone Resorption ◽  
Therapeutic Effect ◽  
Salmon Calcitonin ◽  
Bone Pain ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Therapeutic Uses ◽  
Histological Improvement

Calcitonin is a potent hormonal inhibitor of bone resorption. Its major therapeutic effect is in the treatment of Paget's Disease of bone, in which it has been shown to reduce bone pain, lead to radiological and histological improvement in bone, and to restore abnormal biochemistry towards normal. Some patients are resistant to treatment, and in others resistance may develop during treatment. Although antibodies to pig or to salmon calcitonin develop in almost 50 per cent of treated patients it is only very rarely that resistance may be ascribed to antibodies. There are a number of other clinical states of increased resorption in which the value of calcitonin therapy has yet to be established.

Sign in / Sign up

Export Citation Format

Share Document